1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Idiopathic Pulmonary Fibrosis (IPF): KOL Insight

Idiopathic Pulmonary Fibrosis (IPF): KOL Insight

  • June 2016
  • ID: 4201010
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents




What’s on the KOL ‘wish list’ for the next generation of IPF treatments?
Physicians currently only have two options for Idiopathic Pulmonary Fibrosis (IPF) sufferers: how do they decide between them? Clearly there is a lot riding on the results of various pipeline drug trials. Which of the next generation of new drugs holds the most promise? Is combination therapy the way forward? Or will cost be the final deciding (or debilitating) factor?
Find out in FirstWord’s new report, KOL Insight: IPF. Request sample pages now
Both marketed brands – Ofev and Esbriet - are covered in detail, as well as 9 pipeline therapies undergoing mid-stage clinical testing. The report examines today’s market, looks at future trends and reveals insight from 12 key opinion leaders (KOLs) in North America and Europe.
KOLs share their thoughts, concerns and hopes for the developing IPF treatment pathway, giving clear insight into the factors they believe are most important now and for the future.
"I will start by saying that the current drugs are somewhat helpful, but we still have a desperate need for drugs that make people feel better, that have fewer side effects, and that have a more profound impact on patient outcomes than the currently available drugs.”
US Key Opinion Leader







Expert insight into the IPF treatment landscape
Recently Marketed Drugs

Esbriet (pirfenidone, Roche): Is the high pill burden a real or perceived drawback? What is the biggest benefit over Ofev? Are there any differences between EU and US prescribing habits?
Ofev (nintedanib; Boehringer Ingelheim): What factor is key to choosing Ofev as a first line therapy? How do KOLs feel about the Phase IV combination trial with Esbriet?

Pipeline Drugs

Lebrikizumab (RG-3637; Roche): How do KOLs view subcutaneous administration? Has the halting of AstraZeneca’s IL-13 inhibitor Phase II trial made a difference to KOL sentiment?
Dectrekumab (QAX-576; Novartis): How does this anti-IL-13 antibody compare to lebrikizumab? Is the trial focused on the right patient group?
SAR156597 (Sanofi): KOLs have split opinions on this drug: why? Where do KOLs expect to see SAR156597 in the treatment algorithm?
PBI 4050 (ProMetic Life Sciences): Why are KOLs enthusiastic about this newcomer? What concerns are causing the most unease?
STX-100 (Biogen): How do KOLs rate the drug’s mechanism of action? When do physicians think this drug could be used to best effect?
BMS-986020 (Bristol-Myers Squibb): Interesting in theory only, or showing real promise? Find out what KOLs are saying.
Pamrevlumab (FG-3019, FibroGen): What do KOLs think about targeting a single cytokine as an approach? Is the potential benefit promising enough to get excited about?
PRM-151 (Promedior): How much enthusiasm is there regarding PEM-151’s novel MOA? Is it being viewed as a monotherapy or an add-on?
TD-139 (Galecto Biotech): What perceived advantages are already being identified? Are KOLs viewing the dry-powder formulation as a positive or negative?


Top takeaways

Cost is an underlying concern: Both marketed products are expensive and gaining access is challenging for some patients. How will cost impact future prescribing habits? What happens if combination therapies see good trial results? How will payers manage this?
Patient preference is a key driver: With KOLs seeing no real differences in efficacy between the two marketed products, tolerability become a deciding factor. What concerns do KOLs have about patient response to combination therapies?
Ongoing debate regarding trials: Who is seen as a Phase II front-runner and why? What expectations do KOLs have of the Ofev/Esbriet Phase IV trial? Why is combination therapy becoming such a focus of attention?
Change will be gradual: KOLs know not to expect significant change soon, but which outcomes are most eagerly awaited? Faced with potential combination therapies, new mechanisms of action, better diagnostics and improved safety, what is most prized in the long-term?
Issues with diagnosis: KOLs agree on the benefits of earlier diagnosis but are frustrated – why? Targeting specific patient population segments is desirable but what reasons are given as to why this might be difficult? What new trend did KOLs identify will improve accuracy?


Key Opinion Leaders Interviewed for This Report
KOLs from North America

Dr. Fernando J. Martinez, MD, MS, Adjunct Professor, Department of Internal Medicine, Division of Pulmonary & Critical Care Medicine, Univ. of Michigan.
Dr. Joseph A. Lasky, MD, Tenured Professor of Medicine and the Pulmonary/Critical Care Section Chief at Tulane University Medical School.
Prof. Steven D. Nathan, MD, Medical Director of Inova's Advanced Lung Disease and Transplant Program.
Dr. Paul Wolters, MD, Associate Professor at the School of Medicine, University of California in San Francisco.
Dr. Timothy Blackwell, MD, Professor of Medicine (Allergy, Pulmonary, and Critical Care), Professor of Cancer Biology, and Professor of Cell and Developmental Biology, Director of the Division of Allergy, Pulmonary and Critical Care in the Department of Medicine Vanderbilt University Medical Centre in Nashville.
Dr. Mark Steele, MD, Professor of Medicine in the Department of Allergy, Pulmonary, and Critical Care Medicine at the Vanderbilt University Medical Centre in Nashville.


KOLs from Europe

Prof. Alessandro Zamparelli, Director of the Unit of Respiratory Diseases, School of Medicine, University of Naples.
Prof. Carlo Vancheri, Professor of Respiratory Medicine at the University of Catania, Sicily, Italy, Director of the Regional Centre for Rare Lung Diseases and the Laboratory of Experimental Respiratory Medicine.
Dr. Maria Molina MD, PhD, head of the ILD Unit at Pulmonology Department, Bellvitge University Hospital and the UB-IDIBELL Experimental Pneumology Laboratory.
Dr. Javier Milara Payá, Senior Researcher, Doctor of Pulmonology and Pharmacy at the University General Hospital in Valencia.
Two anonymous German KOLs

A report based on expert knowledge
Key Opinion Leaders Interviewed for This Report
North American KOLs

....
....
....
....
....
....
....
....
....

European KOLs
....
....
....
....

Money Back Guarantee
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.



Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Diagnostics Partnering 2014-2019: Deal trends, players and financials

Global Diagnostics Partnering 2014-2019: Deal trends, players and financials

  • $ 3495
  • November 2019

The Global Diagnostics Partnering 2014-2019 report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading companies.Comprehensive ...

South Africa Central Nervous System Therapeutic Market to 2027 - Regional Analysis and Forecasts by Disease Type, Drug Type, Distribution Channel and Geography

South Africa Central Nervous System Therapeutic Market to 2027 - Regional Analysis and Forecasts by Disease Type, Drug Type, Distribution Channel and Geography

  • $ 3000
  • September 2019

The South Africa Central Nervous System (CNS) Therapeutic market is expected to reach US$ 3,686.91 Mn in 2027 from US$ 2,267.59 Mn in 2018. The market is estimated to grow with a CAGR of 5.6% from 2019-2027.Rising ...

Global Oncology Partnering 2014-2019: Deal trends, players and financials

Global Oncology Partnering 2014-2019: Deal trends, players and financials

  • $ 3495
  • November 2019

The Global Oncology Partnering 2014-2019: Deal trends, players and financials report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading ...


ref:plp2016

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on